Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27744
Abstract: Chronic myeloid leukemia is a clonal malignancy of hematopoietic stem cell that is characterized by the occurrence of t(9;22)(q34;q11.2) translocation, named Philadelphia chromosome. Ruxolitinib is a powerful Janus tyrosine kinase 1 and 2 inhibitor that… read more here.
Keywords: epigenetic modifications; ruxolitinib treatment; cells ruxolitinib; myeloid leukemia ... See more keywords